Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
DOYLESTOWN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York, NY. Details are as follows:
H.C. Wainwright 26th Annual Global Investment Conference
| Date: | September 9-11, 2024 |
| Location: | New York, NY |
| Webcast: | click |
The above presentation is available to access “on-demand”, beginning at 7:00 A.M. (ET), on September 9, 2024. It will be available for 90 days.
Management will be available for one-on-one meetings with institutional investors. To request a meeting, please contact your conference representative.
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website at .
The Company may use, and intends to use, its investor relations website at / as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
(858) 717-2310
